Pegfilgrastim: 6 agencies, 2003–2020
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused pegfilgrastim: all 15 decisive outcomes across 5 agencies were positive or positive with restrictions.
The file has been open for more than a decade: 17.2 years separate the first record, 7 May 2003 at HAS (France), from the most recent, 2020 at PBAC (Australia).
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2020; on this evidence the file is dormant.
4 distinct indication wordings are recorded for pegfilgrastim by the agencies that label one in English (AWMSG, PBAC and SMC).
5 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess pegfilgrastim, on 7 May 2003; TLV (Sweden) did not open a file until 8 Mar 2019 — an unusually long tail of 15.8 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 9 years in total.
3 of the 6 agencies here assessed pegfilgrastim more than once, HAS (France) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for pegfilgrastim.
The full ledger for pegfilgrastim reads 14 recommended, 3 other, 2 deferred and 1 restricted.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PBAC (Australia) | 2020 | Chemotherapy-induced neutropenia | The PBAC recommended the listing of the biosimilar brand of pegfilgrastim, Pelgraz®, on th… | source |
| TLV (Sweden) | 7 Jun 2019 | Ziextenzo ingår i högkostnadsskyddet | general subsidy | source |
| PHARMAC (New Zealand) | 14 Feb 2013 | Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer | PTAC advice: Cost Neutral · decision reached | source |
| HAS (France) | 7 Oct 2009 | Listing (Transparency Committee) | ASMR V | source |
| AWMSG (Wales) | 6 Oct 2008 | Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic che… | recommended with restrictions (full) | source |
15 further decisions for pegfilgrastim, across 4 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- filgrastim — same ATC class L03A — Immunostimulants
- peginterferon alfa-2a — same ATC class L03A — Immunostimulants
- interferon beta-1a — same ATC class L03A — Immunostimulants
- plerixafor — same ATC class L03A — Immunostimulants
- glatiramer — same ATC class L03A — Immunostimulants
- ropeginterferon alfa-2b — same ATC class L03A — Immunostimulants
Coverage: 20 decisions for pegfilgrastim from 6 agencies, 2003 to 2020. Data to 7 Sep 2026. ATC class L03A — Immunostimulants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.